CD4 and neoplasm: Moreover, the combination therapy also increased the number of tumor-infiltrating CD4+ T cells by 5.76-fold, whereas anti-PD-1 and JX monotherapy increased infiltrating CD4+ T cells by 1.71-fold and 3.37-fold, respectively when compared with the controls (figure 6A, B).